X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES STRIDES PHARMA SCIENCE SUVEN LIFESCIENCES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 18.9 19.6 96.2% View Chart
P/BV x 3.7 0.8 437.2% View Chart
Dividend Yield % 0.6 0.6 107.5%  

Financials

 SUVEN LIFESCIENCES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
SUVEN LIFESCIENCES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs2511,147 21.9%   
Low Rs155642 24.1%   
Sales per share (Unadj.) Rs49.1317.2 15.5%  
Earnings per share (Unadj.) Rs9.77.8 123.9%  
Cash flow per share (Unadj.) Rs11.425.1 45.5%  
Dividends per share (Unadj.) Rs1.502.00 75.0%  
Dividend yield (eoy) %0.70.2 330.6%  
Book value per share (Unadj.) Rs60.3274.3 22.0%  
Shares outstanding (eoy) m127.2889.50 142.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.12.8 146.5%   
Avg P/E ratio x20.9114.0 18.3%  
P/CF ratio (eoy) x17.835.7 49.9%  
Price / Book Value ratio x3.43.3 103.2%  
Dividend payout %15.425.5 60.5%   
Avg Mkt Cap Rs m25,82580,058 32.3%   
No. of employees `0001.12.5 42.8%   
Total wages/salary Rs m6134,341 14.1%   
Avg. sales/employee Rs Th5,832.611,325.8 51.5%   
Avg. wages/employee Rs Th571.51,731.4 33.0%   
Avg. net profit/employee Rs Th1,153.8280.1 412.0%   
INCOME DATA
Net Sales Rs m6,25328,394 22.0%  
Other income Rs m233941 24.7%   
Total revenues Rs m6,48529,334 22.1%   
Gross profit Rs m1,9823,965 50.0%  
Depreciation Rs m2131,540 13.8%   
Interest Rs m461,962 2.4%   
Profit before tax Rs m1,9551,403 139.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m71897 738.2%   
Profit after tax Rs m1,237702 176.2%  
Gross profit margin %31.714.0 227.0%  
Effective tax rate %36.76.9 529.8%   
Net profit margin %19.82.5 800.0%  
BALANCE SHEET DATA
Current assets Rs m5,62224,836 22.6%   
Current liabilities Rs m1,16818,993 6.1%   
Net working cap to sales %71.220.6 346.2%  
Current ratio x4.81.3 368.2%  
Inventory Days Days8171 114.7%  
Debtors Days Days36113 31.7%  
Net fixed assets Rs m3,32534,289 9.7%   
Share capital Rs m127895 14.2%   
"Free" reserves Rs m7,54723,651 31.9%   
Net worth Rs m7,67424,546 31.3%   
Long term debt Rs m1415,513 0.1%   
Total assets Rs m9,13565,437 14.0%  
Interest coverage x43.21.7 2,520.4%   
Debt to equity ratio x00.6 0.3%  
Sales to assets ratio x0.70.4 157.7%   
Return on assets %14.04.1 345.0%  
Return on equity %16.12.9 563.5%  
Return on capital %26.06.9 377.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06615,697 32.3%   
Fx outflow Rs m2,001735 272.1%   
Net fx Rs m3,06514,962 20.5%   
CASH FLOW
From Operations Rs m6991,871 37.4%  
From Investments Rs m-65,826 -0.1%  
From Financial Activity Rs m-577-10,157 5.7%  
Net Cashflow Rs m116-2,615 -4.4%  

Share Holding

Indian Promoters % 63.4 27.7 228.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 37.8 -  
FIIs % 0.0 8.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 25.9 140.9%  
Shareholders   37,287 56,241 66.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  FDC LTD.  SUN PHARMA  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 19, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - PLETHICO PHARMA COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS